Trial · NCT04512066
Adverse events117
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 117
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anxiety | Psychiatric disorders | Placebo | 6 | 72 | |
| other | Anxiety | Psychiatric disorders | RO6889450 45 mg (Double-blind Treatment Period) | 3 | 65 | |
| other | Anxiety | Psychiatric disorders | RO6889450 150 mg (Double-blind Treatment Period) | 2 | 68 | |
| other | Anxiety | Psychiatric disorders | Risperidone 4 mg (Double-blind Treatment Period) | 5 | 71 | |
| other | Anxiety | Psychiatric disorders | Placebo - RO6889450 45 mg | 0 | 25 | |
| other | Anxiety | Psychiatric disorders | Placebo - RO6889450 150 mg | 0 | 25 | |
| other | Anxiety | Psychiatric disorders | RO6889450 45 mg (Extension Period) | 0 | 41 | |
| other | Anxiety | Psychiatric disorders | RO6889450 150 mg (Extension Period) | 1 | 45 | |
| other | Anxiety | Psychiatric disorders | Risperidone 4 mg (Extension Period) | 0 | 53 | |
| other | Insomnia | Psychiatric disorders | Placebo | 1 | 72 | |
| other | Insomnia | Psychiatric disorders | RO6889450 45 mg (Double-blind Treatment Period) | 3 | 65 | |
| other | Insomnia | Psychiatric disorders | RO6889450 150 mg (Double-blind Treatment Period) | 5 | 68 | |
| other | Insomnia | Psychiatric disorders | Risperidone 4 mg (Double-blind Treatment Period) | 5 | 71 | |
| other | Insomnia | Psychiatric disorders | Placebo - RO6889450 45 mg | 0 | 25 | |
| other | Insomnia | Psychiatric disorders | Placebo - RO6889450 150 mg | 0 | 25 | |
| other | Insomnia | Psychiatric disorders | RO6889450 45 mg (Extension Period) | 1 | 41 | |
| other | Insomnia | Psychiatric disorders | RO6889450 150 mg (Extension Period) | 1 | 45 | |
| other | Insomnia | Psychiatric disorders | Risperidone 4 mg (Extension Period) | 0 | 53 | |
| other | Agitation | Psychiatric disorders | Placebo | 2 | 72 | |
| other | Agitation | Psychiatric disorders | RO6889450 45 mg (Double-blind Treatment Period) | 0 | 65 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04512066/events